Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system - PubMed (original) (raw)

Review

doi: 10.1159/000106484. Epub 2007 Jul 25.

Affiliations

• PMID: 17652963
• DOI: 10.1159/000106484

Review

Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system

Sakae Tanaka. Am J Nephrol. 2007.

Erratum in

• Am J Nephrol. 2007;27(5):544

Abstract

Bone integrity is maintained through a balance between bone formation and bone resorption, and osteoclasts are primary cells involved in bone resorption. Recent studies have revealed an essential role of macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL) in the development of osteoclasts, and detailed molecular cascades that induce osteoclast differentiation, activation and apoptosis have been clarified. Osteoclasts are involved in various pathologic conditions, such as osteoporosis, rheumatoid arthritis and tumor-induced bone disease, which are characterized by abnormal bone resorption, and the finding of RANKL has provided us a good therapeutic target for such pathologic conditions.

2007 S. Karger AG, Basel

PubMed Disclaimer

Similar articles

• Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
  Tanaka S, Nakamura K, Takahasi N, Suda T. Tanaka S, et al. Immunol Rev. 2005 Dec;208:30-49. doi: 10.1111/j.0105-2896.2005.00327.x. Immunol Rev. 2005. PMID: 16313339 Review.
• [The OPG/RANKL/RANK system and bone resorptive disease].
  Liu JZ, Ji ZL, Chen SM. Liu JZ, et al. Sheng Wu Gong Cheng Xue Bao. 2003 Nov;19(6):655-60. Sheng Wu Gong Cheng Xue Bao. 2003. PMID: 15971575 Review. Chinese.
• RANK/RANKL: regulators of immune responses and bone physiology.
  Leibbrandt A, Penninger JM. Leibbrandt A, et al. Ann N Y Acad Sci. 2008 Nov;1143:123-50. doi: 10.1196/annals.1443.016. Ann N Y Acad Sci. 2008. PMID: 19076348 Review.
• [Genomic approaches to bone and joint diseases. Mutations of RANK, OPG and RANKL genes found in humans].
  Kobayashi Y, Takahashi N. Kobayashi Y, et al. Clin Calcium. 2008 Feb;18(2):202-9. Clin Calcium. 2008. PMID: 18245890 Review. Japanese.
• Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
  Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y. Irie A, et al. Bone. 2007 Aug;41(2):165-74. doi: 10.1016/j.bone.2007.04.190. Epub 2007 May 5. Bone. 2007. PMID: 17560185

Cited by

• Spontaneous Osteoclastogenesis, a risk factor for bone metastasis in advanced luminal A-type breast cancer patients.
  Fernández Vallone V, Borzone FR, Martinez LM, Giorello MB, Choi H, Dimase F, Feldman L, Bordenave RH, Chudzinski-Tavassi AM, Batagelj E, Chasseing NA. Fernández Vallone V, et al. Front Oncol. 2023 Feb 20;13:1073793. doi: 10.3389/fonc.2023.1073793. eCollection 2023. Front Oncol. 2023. PMID: 36890825 Free PMC article.
• Interspecies Single-Cell RNA-Seq Analysis Reveals the Novel Trajectory of Osteoclast Differentiation and Therapeutic Targets.
  Omata Y, Okada H, Uebe S, Izawa N, Ekici AB, Sarter K, Saito T, Schett G, Tanaka S, Zaiss MM. Omata Y, et al. JBMR Plus. 2022 May 16;6(7):e10631. doi: 10.1002/jbm4.10631. eCollection 2022 Jul. JBMR Plus. 2022. PMID: 35866155 Free PMC article.
• Novel cathepsin K inhibitors block osteoclasts in vitro and increase spinal bone density in zebrafish.
  Xue ST, Wang YL, Han XW, Yi H, Jiang W, Si SY, Guo HF, Li ZR. Xue ST, et al. RSC Adv. 2019 Mar 14;9(15):8600-8607. doi: 10.1039/c8ra10338k. eCollection 2019 Mar 12. RSC Adv. 2019. PMID: 35518710 Free PMC article.
• New Function of Cholesterol Oxidation Products Involved in Osteoporosis Pathogenesis.
  Che Y, Yang J, Tang F, Wei Z, Chao Y, Li N, Li H, Wu S, Dong X. Che Y, et al. Int J Mol Sci. 2022 Feb 11;23(4):2020. doi: 10.3390/ijms23042020. Int J Mol Sci. 2022. PMID: 35216140 Free PMC article. Review.
• Inflammatory Arthritis and Bone Metabolism Regulated by Type 2 Innate and Adaptive Immunity.
  Omata Y, Frech M, Saito T, Schett G, Zaiss MM, Tanaka S. Omata Y, et al. Int J Mol Sci. 2022 Jan 20;23(3):1104. doi: 10.3390/ijms23031104. Int J Mol Sci. 2022. PMID: 35163028 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • S. Karger AG, Basel, Switzerland

• Other Literature Sources

  • The Lens - Patent Citations
  • figshare - Data

• Research Materials

  • NCI CPTC Antibody Characterization Program